Souhaitez-vous accéder aux communiqués récents ?

TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of up to 89.2% at 24 months1MonumenTAL-3 is the third positive study in...

Nipocalimab – the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated...

En comparación con los pacientes que recibían únicamente terapia hormonal, los pacientes tenían nueve veces más probabilidades de que tras la cirugía quedara poco o ningún cáncer en la próstata, con...

Par rapport aux patients recevant une hormonothérapie seule, les patients avaient neuf fois plus de chances de ne présenter que peu ou pas de cancer résiduel dans la prostate après la chirurgie, avec...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the...

MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of Johnson & Johnson’s TECVAYLI® as early as second line1TECVAYLI® delivered deep and durable responses, with nearly...

Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients...

Johnson & Johnson presents findings from the largest European real-world dataset for esketamine nasal spray (NS) which confirm its effectiveness and tolerability in a real-world patient...

Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1 Milestone is a testament to ten years of daratumumab experience and...

Application appuyée par des données de la Phase 3 renforçant les schémas thérapeutiques à base de teclistamab comme traitement standard potentiel après au moins une thérapie antérieure1 La...